Author

Margit Horváth

Observed names: Horváth, Margit, M Horvath, M Horváth, M. Horvath, M. Horváth

Institution: Gedeon Richter (Hungary)

Observed institution: Gedeon Richter (Hungary)

ORCID: 0009-0003-4297-1243

Observed ORCID: 0009-0003-4297-1243

OpenAlex ID: A5033523908

Direct healthcare cost of schizophrenia – European overview

2018 · G. Kovács, T. Almási, et al. · European Psychiatry · 68

A systematic review of the indirect costs of schizophrenia in Europe

2018 · A Fasseeh, B Németh, et al. · European Journal of Public Health · 50

A systematic review of health economic models and utility estimation methods in schizophrenia

2018 · Bertalan Németh, Ahmad Fasseeh, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 48

Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone

2017 · Bertalan Németh, Anett Molnár, et al. · Journal of Comparative Effectiveness Research · 38

Healthcare resource use in schizophrenia, EuroSC findings

2017 · A. Millier, M. Horváth, et al. · Journal of Market Access & Health Policy · 14

Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia

2019 · Bertalan Németh, Rita Bendes, et al. · Health Policy and Technology · 8

Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine

2020 · Zoltán Vokó, István Bitter, et al. · Cost Effectiveness and Resource Allocation · 1

Pmh43 - Cost-utility Analysis of Cariprazine Compared to Risperidone Among Patients With Negative Symptoms of Schizophrenia in Selected Central and Eastern European Countries

2018 · B. Nemeth, R. Bendes, et al. · Value in Health · 1

GDP And Population Size – Important Determinants of Schizophrenia-Related Healthcare Costs In The European Countries

2017 · G Kovacs, T Almasi, et al. · Value in Health · 1

Healthcare resource use in schizophrenia sufferers – findings from the EuroSC cohort

2017 · A. Millier, M. Toumi, et al. · European Neuropsychopharmacology · 1

Clinical Drivers Of Economic Models And Utility Mapping Algorithms In Schizophrenia

2017 · B Nemeth, AN Fasseeh, et al. · Value in Health

Indirect Costs and Caregiver Burden of Schizophrenia In European Countries – Results of A Systematic Literature Review

2017 · ANzzz Fasseeh, B Nemeth, et al. · Value in Health

Works count: 14

Citation count: 230

H-index: 6

I10-index: 5